Anxiously Awaiting Exelixis

Waiting for a drugmaker's clinical trial results can be one of the toughest aspects of biotech investing. Exelixis' (Nasdaq: EXEL  ) investors now know how long their latest wait will be, after yesterday's announcement of a phase 3 study for one of the company's lead drugs.

XL184 is Exelixis' proposed small-molecule pill to treat a form of late-stage thyroid cancer. Although XL184 is not Exelixis' first phase 3 drug candidate -- its bile duct tumor treatment XL119 failed in testing two years ago -- it's now Exelixis' only compound in active phase 3 development.

Anti-cancer drug studies usually take a long time to produce clinical trial results, but a quick look at clinicaltrials.gov shows that Exelixis expects the first phase 3 data from XL184 around next December. If it's positive, the progression-free survival (PFS) data expected then could be enough for Exelixis to have XL184 approved and on the market by late 2010.

At best, this is a rough guess at XL184's timeline; it can be very tough to predict when data from cancer clinical trials will come out. The data may face several months' delay if either the placebo group or XL184-treated patients end up surviving longer than expected. Also, if the PFS data next year is not good, XL184 won't necessarily be dead in development. The study will look at other measures of efficacy, like overall survival, that could still get the drug approved -- albeit at a much later date.

There are currently no targeted therapies on the market specifically approved to treat the form of thyroid cancer that XL184 attacks. Other drugmakers like AstraZeneca (NYSE: AZN  ) with Zactima, Onyx Pharmaceuticals (Nasdaq: ONXX  ) with Nexavar, and Pfizer's (NYSE: PFE  ) Sutent have also set their sights on treating thyroid cancer, though.

GlaxoSmithKline (NYSE: GSK  ) still has the option to take control over XL184 if it wants to. If it doesn't decide to do so -- it should make up its mind by this fall -- Exelixis will be free to partner the drug with others. Whatever level of control Exelixis has over XL184, at least we won't have to wait too much longer to finally get some pivotal phase 3 data on the compound.

Exelixis is an active pick of our market-beating Rule Breakers newsletter service. Check out all our other recommendations, and get access to our message boards and exclusive content, with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. Pfizer is an Inside Value pick. Pfizer and Glaxo are Income Investor picks. The Motley Fool owns shares of Exelixis. The Fool has a very patient disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 690061, ~/Articles/ArticleHandler.aspx, 9/20/2014 12:20:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement